JMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "market outperform" rating reissued by investment analysts at JMP Securities in a research note issued on Monday,Benzinga reports. They currently have a $89.00 target price on the stock. JMP Securities' price target points to a potential upside of 310.42% from the stock's previous close.

GPCR has been the subject of a number of other reports. HC Wainwright lowered their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Trading Down 0.2%

Shares of NASDAQ:GPCR opened at $21.69 on Monday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -25.10 and a beta of -1.87. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $47.48. The company has a 50-day moving average price of $23.26 and a 200 day moving average price of $24.14.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GPCR. Zimmer Partners LP boosted its stake in shares of Structure Therapeutics by 77.1% during the first quarter. Zimmer Partners LP now owns 100,776 shares of the company's stock valued at $1,744,000 after purchasing an additional 43,876 shares during the period. Vestal Point Capital LP lifted its holdings in Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after buying an additional 63,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Structure Therapeutics by 3,326.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock valued at $949,000 after buying an additional 53,216 shares during the period. Point72 Europe London LLP boosted its position in Structure Therapeutics by 188.7% in the 1st quarter. Point72 Europe London LLP now owns 90,697 shares of the company's stock valued at $1,570,000 after buying an additional 59,277 shares during the period. Finally, DAFNA Capital Management LLC grew its stake in Structure Therapeutics by 66.2% in the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after acquiring an additional 23,500 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.